The short version of somatotroph fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.
Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.
Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
== Biosynthesis == NAD+ is synthesized through two metabolic pathways. It is produced either in a de novo pathway from amino acids or in salvage pathways by recycling preformed components such as nicotinamide back to NAD+. Although most tissues synthesize NAD+ by the salvage pathway in mammals, much more de novo synthesis occurs in the liver from tryptophan, and in the kidney and macrophages from nicotinic acid.
== Other uses == Clash Royale, a popular mobile strategy game developed and published by Supercell Challenge rating, a rating of challenges in Dungeons & Dragons Chart Rulership or Chart Ruler, in astrology Comfort room, another name for a public toilet Consciousness raising, in social activism Continuing resolution, a type of appropriations legislation in the US Councillor, a title for a public servant, used in Australia and New Zealand Cree language (ISO 639 alpha-2 code CR) Critical reading, a skill measured by the Scholastic Aptitude Test (SAT) Critical Role, a Dungeons & Dragons show Critical Role Productions, the associated media production company Crore, a number representing 10,000,000 in the Hindu-Arabic numeral system Crunchyroll, internet streaming service showing anime Cr$ or ₢, symbol for Brazilian cruzeiro
There were also unpublicised transfers of technology, including the engagement of a US company, Continental Electronics, to design and build a new VLF communications station at Tirunelveli in Tamil Nadu, which was commissioned in the late 1980s.
The toxicological cause of the disease has been attributed to the neurotoxin ODAP which acts as a structural analogue of the neurotransmitter glutamate. Lathyrism can also be caused by deliberate food adulteration.
==== United States market (brands, formats, and recent changes) ==== The leading seller in the e-cigarette market in the US is the Juul e-cigarette, which was introduced in June 2015. As of August 2018, Juul accounts for over 72% of the US e-cigarette market monitored by Nielsen, and its closest competitor—RJ Reynolds' Vuse—makes up less than 10% of the market. Juul rose to popularity quickly, growing by 700% in 2016 alone. On 17 July 2018 Reynolds announced it will debut in August 2018 a pod mod type device similar Juul. The popularity of the Juul pod system has led to a flood of other pod devices hitting the market. Since 2018 the US e-cigarette market has shifted. During January 2020-December 2022, disposable cigarette unit share increased from 24.7% to 51.8%, while prefilled cartridge share decreased from 75.2% to 48.0%. For the four-week period ending December 25, 2022, the top-selling brands were Vuse, JUUL, Elf Bar, NJOY, and Breeze Smoke. In the 52 weeks ended June 15, 2024, Vuse Alto products represented approximately 40% of U.S. e-cigarette sales in stores tracked by NielsenIQ, according to an analyst cited by The Wall Street Journal. In the US the Federal Trade Commission reported that e-cigarette product sales for major reporting manufacturers rose to $2.703 billion in 2019 and then declined to $2.224 billion in 2020, with the FTC noting this may reflect a shift to other market participants. In US retail scanner data, the number of e-cigarette brands increased from 184 in January 2020 to 269 in December 2022.
Sources: en.wikipedia.org
1 December The first draft lottery in the United States since 1942 (and the first in peacetime) was held, and September 14 was the first of the 366 days of the year selected, with Congressman Alexander Pirnie of New York making the first selection.
== History == In 1988, Stark introduced an "Ethics in Patient Referrals" bill concerning physician self-referrals. Some of the ideas in the bill became law as part of the Omnibus Budget Reconciliation Act of 1990. In specific, what is referred to as "Stark I" prohibited a physician referring a Medicare patient to a clinical laboratory if the physician or his/her family member has a financial interest in that laboratory. It was codified in the United States Code, Title 42, Section 1395nn (42 U.S.C. 1395nn, "Limitation on certain physician referrals"). The Omnibus Budget Reconciliation Act of 1993 contained what is known as "Stark II" amendments to the original law. "Stark II" extended the "Stark I" provisions to Medicaid patients and to DHS other than clinical laboratory services. The Centers for Medicare and Medicaid Services has issued rules in the Federal Register to implement Stark Law, including a 2001 "Phase I" final rule, a 2004 "Phase II" interim final rule, and a 2007 "Phase III" final rule.
== Side effects == The Z-drugs are notable for producing side effects such as pronounced amnesia and more rarely hallucinations, especially when used in large doses. On rare occasions, these drugs can produce a fugue state, wherein the patient sleepwalks and may perform relatively complex actions, including cooking meals or driving cars, while effectively unconscious and with no recollection of the events upon awakening. While this effect is rare (and has also been reported to occur with some of the older sedative drugs such as temazepam and secobarbital), it can be potentially hazardous, and so further development of this class of drugs has continued in an effort to find new compounds with further improved profiles. Daytime withdrawal-related anxiety can also occur from chronic nightly nonbenzodiazepine hypnotic usage such as with zopiclone. Side effects can differ within the drug class due to differences in metabolism and pharmacology. For example, long-acting benzodiazepines have problems of drug accumulation especially in the elderly or those with liver disease, and shorter-acting benzodiazepines have a higher risk of more severe withdrawal symptoms. In the case of the nonbenzodiazepines, zaleplon may be the safest in terms of next-day sedation, and − unlike zolpidem and zopiclone − zaleplon has been found to have no association with increased motor vehicle accidents even when taken for middle-of-the-night insomnia due to its ultrashort elimination half-life.
In biochemistry, a cross-linked enzyme aggregate is an immobilized enzyme prepared via cross-linking of the physical enzyme aggregates with a difunctional cross-linker. They can be used as stereoselective industrial biocatalysts.
Sources: en.wikipedia.org
A Border checkpoint is a place where goods or individuals moving across borders are inspected for compliance with border control measures. Access-controlled borders often have a limited number of checkpoints where they can be crossed without legal sanctions. Arrangements or treaties may be established to allow or mandate less-restrained crossings (e.g., the Schengen Agreement). Land border checkpoints (land ports of entry) can be contrasted with the customs and immigration facilities at seaports, international airports, and other ports of entry. Checkpoints generally serve two purposes:
phagocyte Any cell capable of phagocytosis, especially any of various cell types of the immune system which engulf and ingest harmful foreign molecules, bacteria, and dead or dying cells, including neutrophils and macrophages.
At the beginning of the season, Zverev was still ranked too low to receive direct entry into the main draws of ATP Tour events, which forced him to continue playing Challenger events through July. He also needed to enter qualifying for ATP events throughout the year. Zverev did not qualify for either of the first two major singles events of the season. He was able to qualify for his first Masters event at the Miami Open and reached the second round. During the clay-court season, Zverev partnered with his brother Mischa to reach his first career ATP final in doubles at the Bavarian International Tennis Championships. The Zverev brothers finished runner-up to top-seeded Alexander Peya and Bruno Soares. Later that month, he won his second career Challenger title at the Heilbronn Neckarcup to crack the top 100 of the ATP rankings. With a higher ranking, Zverev was directly accepted into Wimbledon. A week before the tournament, he took part in the Boodles Challenge exhibition and surprisingly upset world No. 1 Novak Djokovic in straight sets. Zverev backed up this performance in his Grand Slam tournament main draw debut, defeating Teymuraz Gabashvili in a tight match that lasted until 9–7 in the fifth and final set. He lost in the next round to Denis Kudla. Zverev opted to play on clay after Wimbledon and reached another ATP semifinal at the Swedish Open to put him back in the top 100 after one week out. In August, Zverev returned to the United States and competed in two US Open Series events. He notably upset No.
The principal Cossack émigré leader after 1945 was Nikolai Nazarenko, the self-proclaimed president of the World Federation of the Cossack National Liberation Movement of Cossackia, who enjoyed a prominence in New York as the organizer of the annual Captive Nations parade held every July. In 1978, Nazarenko dressed in his Don Cossack uniform led the Captive Days day parade in New York city, and told a journalist: "Cossackia is a nation of 10 million people. In 1923 the Russians officially abolished Cossackia as a nation. Officially, it no longer exists...America should not spend billions supporting the Soviets with trade. We don't have to be afraid of the Russian army because half of it is made up of Captive Nations. They can never trust the rank and file". The journalist Hal McKenzie described Nazarenko as having "cut a striking figure with his white fur cap, calf-length coat with long silver-sheathed dagger and ornamental silver cartridge cases on his chest". Nazarenko was also the president of Cossack American Republican National Federation, which in turn was part of the National Republican Heritage Groups Council, and he attracted much controversy in the 1980s owing to his wartime career and certain statements he made about Jews. The American journalist Christopher Simpson in his 1988 book Blowback: America's Recruitment of Nazis and Its Effects on the Cold War called Nazarenko a leading Republican activist who made "explicit pro-Nazi, anti-semitic" statements in his speeches.
=== Manganese electrolysis === During the electrowinning of manganese, the addition of selenium dioxide decreases the power necessary to operate the electrolysis cells. China is the largest consumer of selenium dioxide for this purpose. For every tonne of manganese, an average 2 kg selenium oxide is used.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
Results are most often expressed as a percentage of total peak area from a reversed-phase separation. That figure reflects the detection wavelength, gradient and integration choices used by the laboratory. Two valid certificates can therefore quote different values for the same material without either being incorrect.